Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

AC Immune (ACIU) EBIT Margin (2016 - 2026)

AC Immune has reported EBIT Margin over the past 9 years, most recently at 1321.54% for Q1 2026.

  • Quarterly EBIT Margin rose 63503.0% to 1321.54% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 1749.24% through Mar 2026, down 157246.0% year-over-year, with the annual reading at 1940.05% for FY2025, 174825.0% down from the prior year.
  • EBIT Margin was 1321.54% for Q1 2026 at AC Immune, up from 4258.58% in the prior quarter.
  • Over five years, EBIT Margin peaked at 28.52% in Q3 2024 and troughed at 4258.58% in Q4 2025.
  • The 4-year median for EBIT Margin is 1637.47% (2024), against an average of 1749.79%.
  • The largest YoY upside for EBIT Margin was 156656bps in 2025 against a maximum downside of -262111bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 345.21% in 2022, then crashed by -374bps to 1637.47% in 2024, then plummeted by -160bps to 4258.58% in 2025, then surged by 69bps to 1321.54% in 2026.
  • Per Business Quant, the three most recent readings for ACIU's EBIT Margin are 1321.54% (Q1 2026), 4258.58% (Q4 2025), and 1721.62% (Q3 2025).